Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients.

Sara M Tolaney Shom Goel Jorge Nadal Hannelore G Denys Manuel R Borrego Lacey M Litchfield Jiangang Liu Adams K Appiah Yanyun Chen Fabrice Andre

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In this phase II trial, abemaciclib + trastuzumab +/- fulvestrant numerically improved median OS in women with HR+, HER2+ ABC compared to SOC chemotherapy + trastuzumab.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
locally advanced
small cell lung cancer
squamous cell carcinoma
tyrosine kinase
randomized controlled trial
clinical trial
open label
rectal cancer
free survival
chemotherapy induced